Thursday, December 19, 2013
Publication and contact
Parathyroid hormone (PTH)
In vitro and mouse studies suggest PTH could help treat CML.
In a mouse model of CML-like myeloproliferative neoplasia, overexpression of
PTH in the bone marrow microenvironment, which mediates bone turnover,
increased survival and decreased leukemia stem cell proliferation, frequency
and maintenance compared with normal PTH expression. In contrast,
overexpression of PTH in a mouse model of acute myelogenous leukemia (AML)
increased tumor growth. In wild-type mice with established CML-like disease,
PTH plus Gleevec
increased long-term survival compared with either treatment alone or saline.
Next steps could include testing PTH in additional animal models of CML.
Lilly and Co. markets Forteo
a PTH fragment, to treat osteoporosis.
At least seven other companies have therapeutics targeting the PTH receptor
in Phase III or earlier testing for various indications.
AG markets the tyrosine kinase inhibitor Gleevec to treat
AML, CML and other cancers.
Published online Dec. 19, 2013
Patent and licensing status
Krause, D.S. et al. Nat.
published online Oct. 27, 2013;
Contact: David T. Scadden, Massachusetts General Hospital,
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]